Patient Characteristics and Localization of Pathologic PSMA Uptake Detected by 68Ga-PSMA-11 PET/CT and 18F-JK-PSMA-7 PET/CT in Initial Cohort of 10 Patients (Patients 7–11)
| Patient no. | Age (y) | PSA (ng/mL) | Indication | Gleason score | Dose | PSMA+ | Therapeutic consequence | Verification | ||
| Local | Nodal | Distant | ||||||||
| 7 | 52 | 14.9 | BCR after prostatectomy and radiotherapy | 3 + 3 | 68Ga-PSMA PET/CT interpreted as unspecific; no indication for RT of mediastinum | PSMA-negative osteosclerotic bone metastases, detected 9 mo later by 68Ga-PSMA PET/CT | ||||
| 68Ga-PSMA | 152 | 0 | 2 mediastinal* | 0 | ||||||
| 18F-JK-PSMA | 370 | 0 | 0 | 0 | ||||||
| 8 | 73 | 0.8 | BCR after prostatectomy | 4 + 3 | Further PSA increase to 1.13 ng/mL; then, RT of retroperitoneal LN area | PSA decrease to 0.42 ng/mL 4 mo after RT without ADT; 18F-PSMA PET/CT (346 MBq) follow-up confirmed at least 2 retroperitoneal PSMA-positive LNs | ||||
| 68Ga-PSMA | 129 | 0 | 1 retroperitoneal | 0 | ||||||
| 18F-JK-PSMA | 371 | 0 | 3 retroperitoneal | 0 | ||||||
| 9 | 74 | 1.017 | BCR after prostatectomy | 3 + 4 | Without any therapy PSA 0.7 ng/mL after 6 mo and 1.2 ng/mL after 8 mo | n.a. | ||||
| 68Ga-PSMA | 153 | 0 | 0 | 0 | ||||||
| 18F-JK-PSMA | 379 | 0 | 0 | 0 | ||||||
| 10 | 59 | 0.51 | BCR after prostatectomy | 4 + 3 | RT of prostate fossa with regard to R1 and negative PSMA PET scans | PSA decrease to 0.4 ng/mL after 8 mo without ADT | ||||
| 68Ga-PSMA | 110 | 0 | 0 | 0 | ||||||
| 18F-JK-PSMA | 345 | 0 | 0 | 0 | ||||||
| 11 | 69 | 0.46 | BCR after prostatectomy | 4 + 3 | RT of prostate fossa (standard field) | |||||
| 68Ga-PSMA | 76 | 1 | 0 | 0 | ||||||
| 18F-JK-PSMA | 370 | 1 | 0 | 0 | ||||||
↵* Not confirmed by follow-up care.
RT = radiotherapy; LN = lymph node; n.a. = not available.
Patient 6 did not receive 68Ga-PSMA-11 PET/CT and was not included in our direct comparison.